Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis..
Eur J Endocrinol. 179(1), R31-R45.
(2018). Increased CD14+ and decreased CD14- populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients..
Osteoporos Int. 28(3), 991-999.
(2017). Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease..
Br J Haematol. 178(1), 130-136.
(2017).
(2016).
Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment..
Expert Opin Ther Targets. 19(3), 299-306.
(2015). Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia..
Cell Rep. 11(9), 1446-57.
(2015). Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers..
Metabolism. 64(10), 1291-7.
(2015). Denosumab versus zoledronic acid in patients previously treated with zoledronic acid..
Osteoporos Int. 26(10), 2521-7.
(2015). Treatment of multiple myeloma bone disease: experimental and clinical data..
Expert Opin Biol Ther. 15(2), 213-30.
(2015).
(2014).
(2014).
Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment..
Osteoporos Int. 24(7), 2127-32.
(2013).
(2013). Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass..
Bone. 50(5), 1130-4.
(2012). Effects of phosphodiesterase-5 inhibitor vardenafil on testicular androgen-binding protein secretion, the maintenance of foci of advanced spermatogenesis and the sperm fertilising capacity in azoospermic men..
Andrologia. 44 Suppl 1, 144-53.
(2012). Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid..
Endokrynol Pol. 63(4), 312-5.
(2012). Possible zoledronic acid-induced dermatomyositis..
Clin Exp Dermatol. 37(3), 309-11.
(2012). The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass..
Clin Endocrinol (Oxf). 77(6), 816-22.
(2012). Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies..
Tumori. 97(4), 479-83.
(2011). No effect of rosuvastatin in the zoledronate-induced acute-phase response..
Calcif Tissue Int. 88(5), 402-8.
(2011). Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone..
Clin Rheumatol. 30(1), 149-50.
(2011). Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone..
Osteoporos Int. 22(1), 363-7.
(2011). Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1..
J Clin Densitom. 13(2), 190-6.
(2010). Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial..
BJU Int. 106(8), 1181-5.
(2010). Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease..
J Bone Miner Metab. 28(6), 706-12.
(2010).